Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions.
Nodal marginal zone B-cell lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma that affects the lymph nodes. It is a slow-growing cancer that can sometimes become aggressive. NMZL is more common in older adults, but it can occur in younger people as well. The exact cause of NMZL is unknown, but some genetic factors may be involved. NMZL may be associated with Sjogren syndrome, an autoimmune disorder that affects the salivary and tear glands. NMZL can cause symptoms such as painless swelling of the lymph nodes, fever, night sweats, weight loss, and skin rash. The diagnosis of NMZL is based on a biopsy of the affected lymph node and other tests to determine the stage and subtype of the disease. The treatment of NMZL depends on the stage, symptoms, and general health of the patient. It may include chemotherapy, radiation therapy, surgery, or targeted therapy with monoclonal antibodies.
The Nodal Marginal Zone B-Cell Lymphoma drugs in development market research report provide comprehensive information on the therapeutics under development for Nodal Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nodal Marginal Zone B-Cell Lymphoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Nodal Marginal Zone B-Cell Lymphoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 34 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Nodal Marginal Zone B-Cell Lymphoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Nodal Marginal Zone B-Cell Lymphoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Nodal Marginal Zone B-Cell Lymphoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAmgen Inc
Antengene Corp Ltd
AstraZeneca Plc
Aurigene Oncology Ltd
BeiGene Ltd
Bellicum Pharmaceuticals Inc
BioIntegrator
Bristol-Myers Squibb Co
CoImmune Inc
Cullinan Oncology Inc
F. Hoffmann-La Roche Ltd
Fosun Pharma Kite Biotechnology Co Ltd
General Hospital of the People's Liberation Army
Genmab AS
Gilead Sciences Inc
Hutchison MediPharma Ltd
Incyte Corp
InnoCare Pharma Ltd
Institute of Biomedical Research of Salamanca
Johnson & Johnson
Massachusetts General Hospital
Medical College of Wisconsin
MorphoSys AG
Nanjing Sanhome Pharmaceutical Co Ltd
Oncternal Therapeutics
Secura Bio Inc
SIRPant Immunotherapeutics Inc
SymBio Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
UNC Lineberger Comprehensive Cancer Center
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Nodal Marginal Zone B-Cell Lymphoma reports